Stay Curious. Stay Connected.
MailNewsletters♡Donate Now
Sign up
*Password must be at least 8 characters and contain one uppercase letter, one lowercase letter, one number and one symbol.
Already have an account?
By submitting, you consent that you are at least 18 years of age and to receive information about MPR's or APMG entities' programs and offerings. The personally identifying information you provide will not be sold, shared, or used for purposes other than to communicate with you about MPR, APMG entities, and its sponsors. You may opt-out at any time clicking the unsubscribe link at the bottom of any email communication. View our Privacy Policy.
Sign in to your profile
Forgot Password?
New to MPR News?
Welcome back
to news
for you
Reset Password

Enter the username on file and we'll send you a code to reset your password.

Still require assistance or not sure what your User Name is?
Welcome back
to news
for you
Email Verification

A verification code has been emailed to

Still awaiting the code?
Big Books & Bold Ideas with Kerri Miller
Kerri Miller, Kelly Gordon and Marcheta Fornoff

Vaccines are on the horizon. Will the public accept them?

A woman gets a vaccine.
A pharmacist gives Jennifer Haller (left) the first shot in the first-stage safety study clinical trial of a potential vaccine for COVID-19 at the Kaiser Permanente Washington Health Research Institute in Seattle on March 16, 2020. The world's biggest COVID-19 vaccine test got underway July 27 with the first of 30,000 planned volunteers. The experimental vaccine is made by the National Institutes of Health and Moderna Inc., and it's one of several candidates in the final stretch of the global vaccine race.
Ted S. Warren | AP

Go Deeper.

Create an account or log in to save stories.

Like this?

Thanks for liking this story! We have added it to a list of your favorite stories.

After months of mask-wearing, social-distancing and general COVID-fatigue, a vaccine for the coronavirus is on the horizon. According to one tracker, 11 vaccines are in the final testing phase to determine safety and efficacy.

But developing the vaccine is just one finish line. The next step is to mass produce and distribute the vaccine. 

To achieve herd immunity, at least 70 percent of the public must get vaccinated, which could be a challenge. The Pew Research Center found the percentage of U.S. adults who would get a COVID-19 vaccine dropped from 72 percent in May to 51 percent in September. 

In some communities of color where the virus is having a disproportionate effect, some are skeptical about volunteering for vaccine trials or being first in line for a new vaccine. So what’s the best way to proceed? 

Monday at 9 a.m., MPR News host Kerri Miller spoke with two experts about the science and the art of educating the public about the much-hoped-for vaccine.

Guests:

Subscribe to the MPR News with Kerri Miller podcast on: Apple Podcasts, Google Podcasts, Spotify or RSS